デフォルト表紙
市場調査レポート
商品コード
1500098

呼吸器診断市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、検査タイプ別、疾患適応症別、最終用途別、地域別、競合、2019-2029年

Respiratory Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Test Type, By Disease Indication, By End-Use, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 185 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

呼吸器診断市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、検査タイプ別、疾患適応症別、最終用途別、地域別、競合、2019-2029年
出版日: 2024年06月21日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

呼吸器診断の世界市場規模は2023年に57億1,000万米ドルとなり、予測期間では2029年までCAGR 6.73%で着実な成長が予測されています。

世界の呼吸器診断市場は、呼吸器疾患の有病率の増加や、早期かつ正確な診断ソリューションの重視の高まりによって、より広範なヘルスケア産業の中でダイナミックかつ重要なセクターとして浮上しています。この市場には、慢性閉塞性肺疾患(COPD)、喘息、呼吸器感染症などの呼吸器疾患を評価・監視するために設計された多様な診断ツールや機器が含まれます。市場を促進する主な要因としては、大気汚染、タバコの使用、高齢化などの要因により、呼吸器疾患の世界の負担が増加していることが挙げられます。技術の進歩は、高度な画像診断技術から分子診断や迅速なポイントオブケア検査に至るまで、情勢を形成する上で極めて重要な役割を果たしています。これらの技術により、ヘルスケア専門家は呼吸器疾患をより効率的に診断できるようになり、タイムリーな介入と個別化された治療計画が容易になります。

市場概要
予測期間 2025-2029
市場規模:2023年 57億1,000万米ドル
市場規模:2029年 83億6,000万米ドル
CAGR:2024年-2029年 6.73%
急成長セグメント アッセイ&試薬
最大市場 北米

早期診断と疾病管理の重要性に対する認識が高まり、呼吸器診断に対する需要が急増しています。患者もヘルスケアプロバイダーも、呼吸器疾患を発症時に特定することの重要性を認識しており、これにより疾患の進行を緩和し、患者の予後を改善するための予防的対策が可能になります。COVID-19の世界的大流行は、検査手法とインフラストラクチャーの急速な発展を促し、呼吸器診断の重要な役割をさらに強調しています。分子アッセイや血清学的検査を含む診断検査は、COVID-19の原因であるSARS-CoV-2ウイルスに焦点を当てた呼吸器感染症の特定とモニタリングにおいて極めて重要です。市場開拓企業はまた、ポータブルで非侵襲的なデバイスを含む、新しい診断ソリューションを導入するための研究開発にも投資しており、呼吸器検査の分散化を促進し、患者にとってのアクセシビリティを高めています。さらに、診断企業とヘルスケア機関のコラボレーションは、革新的な技術とソリューションをもたらし、呼吸器診断の継続的な進化に貢献しています。

市場促進要因

呼吸器疾患の流行

世界の高齢化

主な市場課題

診断の複雑さ

熟練した人材の確保

主な市場動向

早期かつ正確な診断の重視の高まり

遠隔医療と遠隔モニタリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別(機器とデバイス、アッセイと試薬、サービスとソフトウェア)
    • 検査の種類別(機械的検査、OSA診断検査、画像検査、従来の診断検査、分子診断検査)
    • 疾患別(結核、喘息、肺がん、慢性閉塞性肺疾患、その他)
    • 用途別(病院・診療所、診断研究所、その他)
    • 地域別
    • 企業別(2023)
  • 市場マップ
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 地域別

第6章 アジア太平洋地域の呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第7章 欧州の呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第8章 北米の呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの呼吸器診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別
    • 検査タイプ別
    • 疾患適応症別
    • 最終用途別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の呼吸器診断市場:SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Koninklijke Philips N.V
  • Beckton, Dickson and Company
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • Dragerwerk AG & Co. KGaA
  • Siemens Healthineers AG
  • PerkinElmer Inc.
  • India Medtronic Private Limited
  • Bio-Rad Laboratories, Inc.
  • GE HealthCare Technologies Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 23927

Global Respiratory Diagnostics Market was valued at USD 5.71 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.73% through 2029. The Global Respiratory Diagnostics Market has emerged as a dynamic and crucial sector within the broader healthcare industry, driven by the increasing prevalence of respiratory diseases and a growing emphasis on early and accurate diagnostic solutions. This market encompasses a diverse range of diagnostic tools and devices designed to evaluate and monitor respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and respiratory infections. Key drivers propelling the market include the rising global burden of respiratory illnesses, spurred by factors such as air pollution, tobacco use, and an aging population. Technological advancements play a pivotal role in shaping the landscape of respiratory diagnostics, with innovations ranging from advanced imaging techniques to molecular diagnostics and rapid point-of-care testing. These technologies enable healthcare professionals to diagnose respiratory conditions more efficiently, facilitating timely interventions and personalized treatment plans.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.71 Billion
Market Size 2029USD 8.36 Billion
CAGR 2024-20296.73%
Fastest Growing SegmentAssays & Reagents
Largest MarketNorth America

The increased awareness of the importance of early diagnosis and disease management has prompted a surge in demand for respiratory diagnostics. Patients and healthcare providers alike recognize the significance of identifying respiratory conditions at their onset, allowing for proactive measures to mitigate the progression of diseases and improve patient outcomes. The global COVID-19 pandemic has further underscored the critical role of respiratory diagnostics, driving rapid developments in testing methodologies and infrastructure. Diagnostic tests, including molecular assays and serological tests, have been pivotal in identifying and monitoring respiratory infections, with a focus on the SARS-CoV-2 virus responsible for COVID-19. Market players are also investing in research and development to introduce novel diagnostic solutions, including portable and non-invasive devices, fostering the decentralization of respiratory testing and enhancing accessibility for patients. Additionally, collaborations between diagnostic companies and healthcare institutions contribute to the continuous evolution of respiratory diagnostics, bringing forth innovative technologies and solutions.

Key Market Drivers

Prevalence of Respiratory Diseases

The prevalence of respiratory diseases serves as a paramount driver for the Global Respiratory Diagnostics Market, underscoring the critical need for accurate and timely diagnostic solutions. Chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and respiratory infections, have become increasingly prevalent on a global scale. Contributing factors include environmental pollutants, occupational exposures, lifestyle choices, and an aging population. As the incidence of these respiratory ailments continues to rise, the demand for advanced and efficient diagnostic tools becomes imperative for effective disease management. The aging population is particularly susceptible to respiratory issues, and as the demographic landscape shifts towards an older age structure globally, the burden of respiratory diseases intensifies.

Older individuals often experience age-related respiratory conditions, making early detection and diagnosis crucial for implementing timely interventions. Moreover, the growing awareness among individuals regarding the impact of environmental factors on respiratory health drives a proactive approach to seek respiratory diagnostics for preventive healthcare measures. The COVID-19 pandemic has further accentuated the significance of respiratory diagnostics in the context of global respiratory infections. The heightened focus on testing and monitoring respiratory infections has accelerated advancements in diagnostic technologies. Collectively, the prevalence of respiratory diseases acts as a catalyst, propelling the continuous evolution and expansion of the respiratory diagnostics market to meet the increasing demand for precise and efficient diagnostic solutions in the face of the growing respiratory health challenges worldwide.

Global Aging Population

The Global Respiratory Diagnostics Market is significantly influenced by the aging population worldwide. As demographic patterns shift towards an increasingly older populace, the prevalence of respiratory conditions tends to rise, necessitating a heightened focus on respiratory diagnostics. Aging is associated with a higher susceptibility to respiratory ailments, including chronic obstructive pulmonary disease (COPD), pneumonia, and other age-related respiratory issues. The anatomical and physiological changes that accompany aging, such as reduced lung elasticity and weakened respiratory muscles, contribute to an elevated risk of respiratory disorders.

The demand for advanced diagnostic tools becomes more pronounced to facilitate early detection and proactive management of respiratory diseases in the elderly. The aging population's greater vulnerability to respiratory infections, coupled with a potential decline in immune function, underscores the importance of respiratory diagnostics in this demographic. Timely and accurate diagnostic solutions are essential for tailoring effective interventions and optimizing treatment outcomes for elderly individuals with respiratory conditions. The Global Respiratory Diagnostics Market responds to this demographic imperative by continually innovating diagnostic technologies, embracing portability and non-invasiveness, and enhancing accessibility to diagnostic services. As the aging population continues to expand, the market for respiratory diagnostics is poised to play a pivotal role in addressing the unique healthcare challenges associated with respiratory health in older individuals, contributing to improved quality of life and enhanced healthcare outcomes for this demographic segment.

Key Market Challenges

Complexity in Diagnosis

The Global Respiratory Diagnostics Market grapples with the inherent complexity in diagnosing respiratory conditions, presenting a significant challenge to accurate and timely disease identification. Respiratory diseases often exhibit a spectrum of symptoms that can overlap, making it intricate to differentiate between conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections solely based on clinical presentation. This complexity necessitates sophisticated and multi-faceted diagnostic approaches, including advanced imaging techniques, molecular diagnostics, and pulmonary function tests. Moreover, the challenge of diagnosing respiratory diseases is compounded by the diversity of potential causes, ranging from environmental factors and occupational exposures to genetic predispositions. The intricate interplay of these variables requires comprehensive diagnostic tools that can discern subtle nuances in disease presentation and etiology.

In addition, the need for differential diagnosis is amplified by the existence of comorbidities, where individuals may concurrently experience multiple respiratory conditions. Unraveling this diagnostic complexity is crucial for tailoring appropriate treatment strategies and interventions. Advanced technologies, such as precision medicine and personalized diagnostics, are increasingly being explored to address the intricate nature of respiratory disease diagnosis by considering individual patient characteristics and genetic factors. As the Global Respiratory Diagnostics Market continues to evolve, the industry faces the ongoing challenge of developing and refining diagnostic tools that can navigate the intricate landscape of respiratory diseases. Overcoming the complexity in diagnosis requires ongoing research, technological innovation, and collaborative efforts to enhance the specificity and sensitivity of diagnostic methods, ultimately improving patient outcomes and optimizing respiratory healthcare delivery.

Availability of Skilled Personnel

The availability of skilled personnel poses a significant challenge to the Global Respiratory Diagnostics Market, impacting the effective implementation and utilization of advanced diagnostic technologies. Operating and interpreting results from sophisticated respiratory diagnostic tools, such as molecular assays, imaging techniques, and pulmonary function tests, often requires specialized training and expertise. However, there is a shortage of healthcare professionals with the necessary skills and proficiency in utilizing these technologies, particularly in resource-limited settings and underserved regions. The complexity of respiratory diseases and the diverse range of diagnostic modalities available further exacerbate the challenge of skilled personnel availability. Healthcare professionals need to possess a comprehensive understanding of respiratory anatomy and physiology, as well as proficiency in interpreting diagnostic results accurately to facilitate timely diagnosis and appropriate treatment decisions.

Staying abreast of advancements in respiratory diagnostics requires continuous education and training, which may not always be readily accessible to healthcare professionals in all regions. Addressing the shortage of skilled personnel in respiratory diagnostics requires concerted efforts from various stakeholders. This includes investing in specialized training programs and continuing education opportunities for healthcare professionals to enhance their diagnostic skills. Collaboration between academic institutions, healthcare organizations, and industry partners can facilitate the development of tailored training programs that address the specific needs of respiratory diagnostics. Also, leveraging telemedicine and digital health platforms can extend the reach of skilled personnel to remote or underserved areas, ensuring broader access to respiratory diagnostic expertise and improving healthcare outcomes for patients worldwide.

Key Market Trends

Increased Emphasis on Early and Accurate Diagnosis

The Global Respiratory Diagnostics Market is witnessing a pronounced trend marked by an increased emphasis on early and accurate diagnosis of respiratory conditions. This shift is driven by a recognition of the substantial benefits associated with timely disease identification, leading to improved patient outcomes and more effective management of respiratory disorders. Advances in diagnostic technologies, including molecular testing, advanced imaging modalities, and novel biomarkers, have facilitated a more precise and rapid diagnosis of respiratory diseases. Early diagnosis is particularly crucial in respiratory health, as it enables healthcare professionals to initiate timely interventions, tailor treatment plans, and prevent the progression of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. The integration of point-of-care testing, offering quick and convenient diagnostic results, further supports this trend, especially in settings where immediate decision-making is imperative.

The growing understanding of the impact of respiratory diseases on public health has heightened the importance of proactive healthcare measures. Screening programs and routine respiratory diagnostics have become integral components of preventive healthcare strategies. Patients and healthcare providers alike recognize that early detection not only enhances treatment efficacy but also reduces the economic burden associated with advanced-stage respiratory diseases. As the Global Respiratory Diagnostics Market continues to evolve, the increased emphasis on early and accurate diagnosis is expected to drive innovation, encourage research and development, and ultimately contribute to a paradigm shift in respiratory healthcare, fostering a future where proactive diagnostics play a central role in preserving respiratory health worldwide.

Telehealth and Remote Monitoring

Telehealth and remote monitoring have emerged as transformative trends in the Global Respiratory Diagnostics Market, especially accelerated by the paradigm shift induced by the COVID-19 pandemic. These technologies play a pivotal role in reshaping how respiratory diagnostics are conducted, providing opportunities for remote consultations, continuous patient monitoring, and accessible healthcare delivery. The adoption of telehealth platforms facilitates virtual consultations, enabling individuals to connect with healthcare professionals for respiratory assessments without the need for physical visits to medical facilities. This has proven particularly valuable in ensuring continued respiratory care during times of social distancing and lockdowns. Remote monitoring technologies offer a real-time and continuous assessment of respiratory parameters, providing crucial data for the early detection and management of respiratory conditions.

Wearable devices, smart inhalers, and other connected technologies enable healthcare providers to remotely track patients' respiratory health, optimizing personalized treatment plans and improving overall disease management. These innovations not only enhance patient convenience but also contribute to better adherence to treatment regimens and timely interventions. The integration of telehealth and remote monitoring in the respiratory diagnostics landscape not only addresses the challenges posed by geographical barriers but also supports proactive healthcare measures. Patients with chronic respiratory conditions can benefit from regular monitoring and timely adjustments to their treatment plans, reducing the risk of exacerbations and hospitalizations. As the Global Respiratory Diagnostics Market continues to evolve, the synergy between telehealth, remote monitoring, and respiratory diagnostics is poised to redefine patient care, fostering a future where healthcare is increasingly accessible, personalized, and proactive.

Segmental Insights

Type Insights

Based on Type, Assays & Reagents have emerged as fastest growing segment in the Global Respiratory Diagnostics Market in 2023. This is ascribed due to its fundamental role in detecting and analyzing respiratory infections. Assays and reagents form the core components of diagnostic tests, enabling the identification of respiratory pathogens, biomarkers, and specific antibodies. The growing prevalence of respiratory diseases and infections fuels the demand for accurate and efficient diagnostic tools. Ongoing advancements in assay technologies contribute to the segment's dominance, facilitating rapid and precise respiratory diagnostics. The Assays & Reagents segment's central role in enhancing diagnostic capabilities positions it as a key driver, influencing the trajectory of the Global Respiratory Diagnostics Market.

End-Use Insights

Based on End-Use, Hospitals and Clinics have emerged as dominating segment in the Global Respiratory Diagnostics Market in 2023. Hospitals and clinics play a pivotal role as primary destinations for individuals seeking respiratory diagnostic services. Patients frequently rely on these healthcare facilities for initial evaluation, diagnosis, and treatment of respiratory conditions, resulting in a significant demand for diagnostic tests. By offering comprehensive healthcare services, including respiratory diagnostics, within a single location, hospitals and clinics promote convenience, encouraging patients to undergo diagnostic procedures and promptly address respiratory ailments. Moreover, hospitals often feature specialized departments and respiratory care units staffed with skilled healthcare professionals, such as pulmonologists and respiratory therapists. These experts possess the knowledge and proficiency to administer and interpret intricate respiratory diagnostic tests, thereby elevating the standard of care provided.

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Respiratory Diagnostics Market in 2023. North America's advanced healthcare infrastructure features cutting-edge diagnostic facilities and state-of-the-art medical technologies, enabling early detection and diagnosis of respiratory conditions, thus propelling market expansion. With a notable prevalence of respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, the region undergoes extensive diagnostic testing, further solidifying its market dominance. Moreover, North America leads the way in developing and adopting innovative respiratory diagnostic technologies, including advanced imaging methods, molecular diagnostics, and point-of-care testing systems, reinforcing its stronghold in the market.

Key Market Players

Koninklijke Philips N.V

Becton, Dickinson and Company

Thermo Fisher Scientific Inc.

Abbott Laboratories Inc.

Dragerwerk AG & Co. KGaA

Siemens Healthineers AG

PerkinElmer Inc.

India Medtronic Private Limited

Bio-Rad Laboratories, Inc.

GE HealthCare Technologies Inc.

Report Scope:

In this report, the Global Respiratory Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Diagnostics Market, By Type:

    Instruments and Devices Assays & Reagents Services & Software

Respiratory Diagnostics Market, By Test Type:

    Mechanical Tests OSA Diagnostic Test Imaging Tests Traditional Diagnostic Test Molecular Diagnostic Test

Respiratory Diagnostics Market, By Disease Indication:

    Tuberculosis Asthma Lung Cancer Chronic Obstructive Pulmonary Disease Others

Respiratory Diagnostics Market, By End-Use:

    Hospitals and Clinics Diagnostics Laboratory Others

Respiratory Diagnostics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Respiratory Diagnostics Market.

Available Customizations:

Global Respiratory Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Instruments and Devices, Assays & Reagents, Services & Software)
    • 5.2.2. By Test Type (Mechanical Tests, OSA Diagnostic Test, Imaging Tests, Traditional Diagnostic Test, Molecular Diagnostic Tests)
    • 5.2.3. By Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, Others)
    • 5.2.4. By End-Use (Hospitals and Clinics, Diagnostics Laboratory, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Test Type
    • 5.3.3. By Disease Indication
    • 5.3.4. By End-Use
    • 5.3.5. By Region

6. Asia Pacific Respiratory Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Test Type
    • 6.2.3. By Disease Indication
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Respiratory Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Disease Indication
        • 6.3.1.2.4. By End-Use
    • 6.3.2. India Respiratory Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Disease Indication
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Australia Respiratory Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Disease Indication
        • 6.3.3.2.4. By End-Use
    • 6.3.4. Japan Respiratory Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Test Type
        • 6.3.4.2.3. By Disease Indication
        • 6.3.4.2.4. By End-Use
    • 6.3.5. South Korea Respiratory Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Test Type
        • 6.3.5.2.3. By Disease Indication
        • 6.3.5.2.4. By End-Use

7. Europe Respiratory Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Test Type
    • 7.2.3. By Disease Indication
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Respiratory Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Disease Indication
        • 7.3.1.2.4. By End-Use
    • 7.3.2. Germany Respiratory Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Disease Indication
        • 7.3.2.2.4. By End-Use
    • 7.3.3. Spain Respiratory Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Disease Indication
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy Respiratory Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Disease Indication
        • 7.3.4.2.4. By End-Use
    • 7.3.5. United Kingdom Respiratory Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Disease Indication
        • 7.3.5.2.4. By End-Use

8. North America Respiratory Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Test Type
    • 8.2.3. By Disease Indication
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Respiratory Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Disease Indication
        • 8.3.1.2.4. By End-Use
    • 8.3.2. Mexico Respiratory Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Disease Indication
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Canada Respiratory Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Disease Indication
        • 8.3.3.2.4. By End-Use

9. South America Respiratory Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Test Type
    • 9.2.3. By Disease Indication
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Respiratory Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Disease Indication
        • 9.3.1.2.4. By End-Use
    • 9.3.2. Argentina Respiratory Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Disease Indication
        • 9.3.2.2.4. By End-Use
    • 9.3.3. Colombia Respiratory Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Disease Indication
        • 9.3.3.2.4. By End-Use

10. Middle East and Africa Respiratory Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Test Type
    • 10.2.3. By Disease Indication
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Respiratory Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Disease Indication
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Saudi Arabia Respiratory Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Disease Indication
        • 10.3.2.2.4. By End-Use
    • 10.3.3. UAE Respiratory Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Disease Indication
        • 10.3.3.2.4. By End-Use
    • 10.3.4. Egypt Respiratory Diagnostics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Test Type
        • 10.3.4.2.3. By Disease Indication
        • 10.3.4.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Respiratory Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Koninklijke Philips N.V
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Beckton, Dickson and Company
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Abbott Laboratories Inc.
  • 15.5. Dragerwerk AG & Co. KGaA
  • 15.6. Siemens Healthineers AG
  • 15.7. PerkinElmer Inc.
  • 15.8. India Medtronic Private Limited
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. GE HealthCare Technologies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer